Premium
Pharmacokinetic/pharmacodynamic relationship of cefquinome against P asteurella multocida in a tissue‐cage model in yellow cattle
Author(s) -
Shan Q.,
Yang F.,
Wang J.,
Ding H.,
He L.,
Zeng Z.
Publication year - 2014
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12076
Subject(s) - pasteurella multocida , pharmacokinetics , pharmacodynamics , pharmacology , antimicrobial , antibiotics , cephalosporin , dosing , ex vivo , in vivo , chemistry , microbiology and biotechnology , in vitro , medicine , biology , bacteria , biochemistry , genetics
The cephalosporin antimicrobial drug cefquinome was administered to yellow cattle intravenously (i.v.) and intramuscularly (i.m.) at a dose of 1 mg/kg of body weight in a two‐period crossover study. The pharmacokinetic ( PK ) properties of cefquinome in serum, inflamed tissue‐cage fluid (exudate), and noninflamed tissue‐cage fluid (transudate) were studied using a tissue‐cage model. The in vitro and ex vivo activities of cefquinome in serum, exudate, and transudate against a pathogenic strain of P asteurella multocida ( P . multocida ) were determined. A concentration‐independent antimicrobial activity of cefquinome was confirmed for levels lower than 4 × MIC . Integration of in vivo pharmacokinetic data with the in vitro MIC provided mean values for the time that drug levels remain above the MIC ( T > MIC ) in serum was 14.10 h after intravenous and 14.46 h after intramuscular dosing, indicating a likely high level of effectiveness in clinical infections caused by P . multocida of MIC 0.04 μg/mL or less. These data may be used as a rational basis for setting dosing schedules, which optimize clinical efficacy and minimize the opportunities for emergence of resistant organisms.